Jones Day Welcomes Patent Litigator Andrew Rankine to Sydney Office

Jones Day announced that Andrew Rankine has joined the firm's intellectual property practice as a partner in its Sydney office.

A patent litigator who focuses on the life sciences sector, Mr. Rankine has extensive experience handling complex and high-profile patent disputes for global leaders in the pharmaceutical, biotechnology, and medical device industries.

Mr. Rankine's client work has also involved navigating Australia’s regulatory regime for therapeutic goods as well as the country's Commonwealth Government reimbursement system, the Pharmaceutical Benefits Scheme. He has counseled numerous life sciences companies on IP portfolio management, freedom to operate, patent validity, patent term extensions, and related matters.

"Andrew comes to Jones Day with successful experience working on complicated patent disputes across multiple industry sectors " said Anthony M. Insogna, who leads Jones Day's global Intellectual Property Practice. "That experience will benefit Jones Day clients that operate in Australia where patent disputes play a crucial role in the life sciences sector. I am very happy to welcome him to Jones Day."

"Andrew joins our Australian IP team which is recognized as one of the pre-eminent IP litigation groups in the country ," said John Emmerig, partner-in-charge of the firm's Sydney office. "His experience with Australia's life sciences companies will be a valuable asset as we continue to grow and serve clients in the region. I look forward to his contributions and I welcome him to Jones Day."

Added Chris Ahern, partner-in-charge of Jones Day in Australia, "Andrew's arrival sends a clear message that Jones Day remains committed to providing our clients access to the top-tier IP legal talent in the region. He is a very good fit for us, and I look forward to his contributions."

Mr. Rankine is listed in leading directories including Best Lawyers in Australia 2018 (Life Sciences Practice) and Doyle's Guide 2018 (Contentions Intellectual Property).